July 28, 2020 -- Recursion has acquired Vium to advance its technologies and grow its drug discovery pipeline of over 30 programs.
Vium's platform combines computer vision, machine learning, and sensor technologies to noninvasively collect and derive insights from digital biomarkers in preclinical in vivo research. The acquisition will augment Recursion's in vitro datasets and bolster its core technologies.
Financial terms of the acquisition were not disclosed.
Already have an account? Sign in Here
To access all ScienceBoard content create a free account now: